Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.

Thomas J KaleyKatherine S PanageasElena I PentsovaIngo K MellinghoffCraig NolanIgor GavrilovicLisa M DeAngelisLauren E AbreyEric C HollandAntonio OmuroMario E LacoutureEmmy LudwigAndrew B Lassman

Published in: Annals of clinical and translational neurology (2020)

Combining the mTOR inhibitor temsirolimus dosed at 115 mg weekly and the AKT inhibitor perifosine dosed at 100 mg daily (following 600 mg load) is tolerable in heavily pretreated adults with recurrent MGs.

Keyphrases

clinical trial
cell proliferation
signaling pathway
physical activity
open label
study protocol
randomized controlled trial
phase ii
double blind